

86. Khan A, Raza S, Khan Y, Aksoy T, Khan M, Weinberger Y, et al. Current updates in the medical management of obesity. *Recent Pat Endocr Metab Immune Drug Discov* 2012; 6:117-28; PMID:22435392; <http://dx.doi.org/10.2174/187221412800604644>.
87. Oral EA. Leptin for type 1 diabetes: coming onto stage to be (or not?). *Pediatr Diabetes* 2012; 13:68-73; PMID:21917108; <http://dx.doi.org/10.1111/j.1399-5448.2011.00797.x>.
88. Freeman JS. Insulin analog therapy: improving the match with physiologic insulin secretion. *J Am Osteopath Assoc* 2009; 109:26-36; PMID:19193822.
89. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, et al.; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet* 2012; 379:1498-507; PMID:22521072; [http://dx.doi.org/10.1016/S0140-6736\(12\)60205-0](http://dx.doi.org/10.1016/S0140-6736(12)60205-0).
90. Tahrani AA, Bailey CJ, Barnett AH. Insulin degludec: a new ultra-longacting insulin. *Lancet* 2012; 379:1465-7; PMID:22521058; [http://dx.doi.org/10.1016/S0140-6736\(12\)60527-3](http://dx.doi.org/10.1016/S0140-6736(12)60527-3).